Family Encyclopedia >> Health

World's First Bioresorbable Pacemaker: Dissolves Safely in the Body After Use

Experts from Northwestern and George Washington Universities have pioneered the world's first transient pacemaker—a fully biocompatible device that dissolves harmlessly in the body once its job is done.

Temporary cardiac pacing typically requires sewing electrodes into the heart muscle post-surgery or while awaiting a permanent pacemaker. Wires extend from the chest to an external box that regulates heart rate via electrical pulses. Once normal rhythm returns, another surgery removes the electrodes.

Though uncommon, risks of these temporary pacemakers include infections, tissue damage, bleeding, and clots. Most critically, they severely restrict patient mobility—often for weeks.

Detailed in a recent Nature study, this innovative device matches traditional performance with far greater freedom for patients.

A Fully Biocompatible Innovation

Weighing just half a gram and a mere 250 microns thick, this ultra-flexible device adheres directly to heart tissue, delivering precise electrical impulses via integrated electrodes. Unlike conventional models, it's entirely wireless, powered remotely by an external NFC antenna.

Its standout feature: complete biocompatibility. Every component naturally breaks down in body fluids, with dissolution rates tunable by material composition and thickness. In trials, it typically resolves in 5-7 weeks.

"The circuit is implanted directly on the heart's surface and activated remotely. Within weeks, it degrades naturally, eliminating the need for surgical removal," explains Dr. Rishi Arora, cardiologist at Northwestern Medicine.

World s First Bioresorbable Pacemaker: Dissolves Safely in the Body After UseWorld s First Bioresorbable Pacemaker: Dissolves Safely in the Body After Use

"This transient pacemaker is remarkable," says Dr. Duc Thinh Pham of Northwestern University, a veteran surgeon with over 2,000 heart procedures. "It tackles post-op pacing needs from blocks or arrhythmias while enhancing comfort, mobility, and recovery. If it advances, it could transform patient outcomes."

Tested successfully on mouse, rat, rabbit, and dog hearts, plus human tissue models, the device shows strong promise. The team aims for clinical availability within five years, pending further trials.